Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.
Abou-Alfa, G K
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 06 2018 - 1402-1408 p. digital
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1569-8041
10.1093/annonc/mdy101 doi
Carcinoma, Hepatocellular--pathology
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Hydrolases--therapeutic use
Liver Neoplasms--pathology
Male
Middle Aged
Palliative Care
Polyethylene Glycols--therapeutic use
Prognosis
Survival Rate
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 06 2018 - 1402-1408 p. digital
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1569-8041
10.1093/annonc/mdy101 doi
Carcinoma, Hepatocellular--pathology
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Hydrolases--therapeutic use
Liver Neoplasms--pathology
Male
Middle Aged
Palliative Care
Polyethylene Glycols--therapeutic use
Prognosis
Survival Rate